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 Heat-shock protein (Hsp90) a group of molecular chaperones responsible for managing 
protein folding and quality control in cell environment. Hsp90 requires a series of co-
chaperones to assemble into a super-chaperone complex for its function. The current study is 
piloted to perform antibacterial, antifungal, anti-inflammatory, anti-Parkinson’s and 
antioxidant activities of Hsp90 inhibitors. The compounds S30 and S47 were synthesized and 
the maximum tolerable dose was found to be 2000 mg/kg, animals were administered with a 
dose of 100 mg/kg bd. wt and 200 mg/kg bd. wt. From the results dose dependent reduction in 
symptoms like muscular rigidity, ptosis, tremor, bradykinesia, gait alteration, righting reflex, 
swim test and locomotor behavior were observed. The histopathological studies of drug 
treated also showed the restoration. The two test drugs S30 and S47 possess antibacterial, 
antifungal, anti-inflammatory, anti-Parkinson’s and antioxidant activities. Further study is 
needed to confirm the exact mechanism of action of the test drugs S30 and S47. 
Please cite this article in press as Dr. M. Ganga Raju et al. Antimicrobial, Anti-Inflammatory, And Anti-Parkinson’s Screening of 
Azomethine Analogues Through Hsp90 Inhibition. Indo American Journal of Pharmaceutical Research.2017:7(04). 
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INTRODUCTION 
Heat shock proteins (Hsps) are a family of greatly sealed stress proteins which can be persuaded by environmental stress such 
as heat, hypoxia, DNA damage or UV radiation to regulate cell breakdown and defend prokaryotic and eukaryotic cells from 
detrimental exogenous stimulus. Heat shock proteins are highly abundant proteins in eukaryotic cells, constituting about 1-2% of total 
proteins in unstressed cells and increasing to 4-6% of cellular proteins under stress. Hsp90 is an ATP-reliant molecular chaperone 
which is essential in eukaryotes. It is required for the activation and stabilization of a wide variety of client proteins. Client proteins of 
Hsp90 play a central pathogenic role in human diseases including cancer, neurodegenerative diseases and viral infections [1]. 
 
MATERIALS AND METHODS  
Synthesis of compounds  
Compounds S30 and S47 were synthesized and characterized as reported previously [2]. 
 
HO OH
CH N
                        HO OH
CH N CH3
 
 
S30                                                                       S47 
 
Figure: 1 Structure of test compounds. 
 
Animals Studies 
Healthy adult Sprague Dawley rats of 180-250 gm and Swiss albino mice 20-30 gm were selected for the study. The animals 
were acquired from Gentox laboratories, Hyderabad. The animals were accommodated according to CPCSEA guidelines (under 
standard temperature condition). They were given a pellet diet and water ad libitum. The ethical clearance was obtained from 
Institutional Animal Ethics Committee (IAEC) before the experiment (Reg. no.1175/PO/Ere/S/08/CPCSEA). 
 
Acute toxicity studies  
Acute toxicity study was accomplished on compounds S30 and S47 following OECD guidelines (425). The dosage for the 
pharmacological studies was selected as 1/10
th
 of the highest dose (2000 mg/kg) administered.   
 
Experimental design 
Antibacterial and antifungal activity 
The antimicrobial activity of the test compounds were performed using agar disc diffusion method to reveal the minimal 
inhibitory concentrations (MIC), i.e., the lowest concentrations of the compounds that inhibit the visible growth of the tested 
microorganism. Petri plates containing 20 ml of Nutrient agar (NA) media for bacteria and Sabourand’s dextrose agar (SDA) for  fungi 
were used. After solidification of the media, ditch was made in the plates with the help of cup-borer (0.85 cm) and then the test 
compound was inoculated into the well. Ciprofloxacin was used as a standard for bacteria and Fluconazole was used as a positive 
control for fungi. Plates inoculated with bacteria incubated for 24 h at 37 °C and the fungal culture was incubated for 48 h at 25 °C 
[3]. The inhibition zone diameters were measured in millimeters. All the tests were performed in triplicate and the average was taken 
as final reading. 
 
Anti-inflammatory activity 
Carrageenan induced paw edema model 
The anti-inflammatory activity was evaluated using carrageenan-induced paw edema in the rat model. Sprague Dawley rats 
are used and acute paw edema was induced by sub-plantar injection of carrageenan suspension into the right hind paw of each rat. The 
left hind paw was injected with the same volume of 0.1 ml of normal saline. Indomethacin (10 mg/kg bd.wt dose orally) was used as 
standard.  Rats were pre-treated with test drugs (100 mg/kg and 200 mg/kg) and standard drug 1 h prior to carrageenan administration. 
The paw size was measured in mm using plethysmometer before (0 min) and at 1 h, 2 h, 3 h and 4 h after carrageenan administration.  
A total of 36 rats were used. The rats were divided into six groups with six animals in each group [4].  
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Formalin-induced paw edema model 
The anti-inflammatory activity was measured using formalin-induced paw edema in the rat model. Female Sprague Dawley 
rats are used and edema was induced by sub-plantar injection of formalin solution into the right hind paw of each rat. The left hind 
paw was injected with the same volume of 0.1 ml of normal saline. Indomethacin (10 mg/kg bd. wt. dose orally) was used as standard.  
Rats were pre-treated with test drugs (100 mg/kg and 200 mg/kg) and standard drug 1 h prior to formalin administration. The paw size 
was measured in mm using plethysmometer before (0 min) and at 1 h, 2 h, 3 h and 4 h after formalin administration.  A total of 36 rats 
were used. The rats were divided into six groups with six animals in each group [5]. 
The % inhibition was calculated by the following formula. 
 
% inhibition in paw edema = (1−Vt/Vc) ×100 
 
Where Vt and Vc is the mean increase in paw thickness in treated and control groups respectively. 
 
Anti-Parkinson’s activity 
Reserpine induced Parkinson’s model 
Swiss albino male mice 20-30 gm were used. The animals received reserpine of i.p. 5 mg/kg bd. wt. of dissolved in 1% 
glacial acetic acid solution 24 h before the test. The test compounds S30 and S47 at doses of 100 mg/kg and 200 mg/kg and standard 
drugs administered 30 min prior recording the observations. Bromocriptine 2.5 mg/kg was used as standard drug.  The various 
parameters like muscular rigidity, ptosis, tremor, bradykinesia, catalepsy, righting reflex, actophotometer investigations were 
measured [6]. 
 
Haloperidol induced Parkinson’s model  
Sprague Dawley rats weighing 180-200 g of either sex were used. The animals received haloperidol 2 mg/kg bd. wt. i.p 1 h 
before the test to induce Parkinson’s disease. The animals were dosed for 7 days. On the seventh day, animals were observed for 30 
minutes post injection. The test compounds S30 and S47 at doses of 100 mg/kg and 200 mg/kg and standard drugs administered 30 
min prior recording the observations. Bromocriptine 2.5 mg/kg bd.wt. used as standard drug.  The various parameters like muscular 
rigidity, ptosis, tremor, bradykinesia, catalepsy, righting reflex, actophotometer test were measured [7]. 
 
Muscular rigidity 
For the investigation of muscular rigidity, the mice/rat was suspended by its forelimbs on a metal rod of 0.25 cm in diameter 
located approximately 20 cm above the surface. The time taken by the animal to remain on the rod (maximum 1 min) was recorded. 
To assess rigidity in a bracing task, the number of steps taken with each forelimb when the mouse is pushed sideways over a distance 
of 50 cm was recorded [6]. 
 
Palpebral ptosis 
The irregular bending of the upper lid, caused by partial or total decrement in elevator muscle function was scored in the 
following way - 0 wide-open eyes, 2 half-open eyes, 4 eyes completely closed, 1 and 3 indicating intermediate values [6]
. 
 
Tremor 
Tremor also defined as shaking, the phasic tremor of the whole body was evaluated visually in mice utilizing the rating scale 
- 0 no tremor, 1 occasional isolated twitch, 2 moderate tremor associated with short periods of calmness, 3 pronounced continuous 
tremor [6]. 
 
Akinesia/bradykinesia 
It is the diminished capability to start movements or akinesia test, the mouse was held by the tail so that animal is standing by 
his forelimbs and moving on his own. The number of steps taken with both forelimbs was recorded for 30 s [6].  
 
Catalepsy 
It is measured by  placing the animal forepaws on a horizontal  wooden bar (for mice 0.7 cm diameter & 4 cm above the table 
top, for rats 2-5 cm diameter & 6 cm above the top) the time until the animal removed forepaws from the bar  was recorded, with a 
maximum cut off time of 3 min [6]. 
 
Gait alteration  
The variation of the march was assessed only once by recording footprints (can be done by marking mice’s paws with ink). 
Uninterrupted walking over a sheet of paper allows analysis of gait patterns and pathways [6]. 
 
Righting reflex 
The righting reflex was assessed by rotating the mouse onto its back five times. Normal mice immediately turn themselves 
over, to right themselves onto all four feet. Righting reflex was scored as follows – 0 -no impairment, 1- on side one to two times, 2- 
on side three to four times, 3- on side five times, 4 - on back one to two times, 5 - on back three to four times, 6 - on back five times, 7 
- sluggish when placed on back and 8 - righting response absent when on back and tail pinched [6]. 
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Actophotometer 
Each animal placed in the actophotometer and the readings of interrupting the light electrodes were recorded for 3min [8]. 
 
Swim test 
Each mouse was introduced individually into a pool (45 cm long; 22 cm wide diameter and 20 cm high) filled with 10 cm 
deep water (21-23°C). Mice were allowed to swim maximum time 5 minutes. The time was recorded until the mice float on water 
without any movement [6]. 
 
Histopathological studies  
Brain of normal control, haloperidol control, test S30 (200 mg/kg) and test S47 (200 mg/kg) treated groups and standard 
bromocriptine were stored in containers for 12 h in 10% formalin solution and subjected to histopathological studies. Observed 
microscopically for histopathological changes i.e., normal, damaged and recovered brain was studied and compared. The results were 
shown in Figure 2. 
 
In vitro Antioxidant studies 
Antioxidant studies such as reducing power assay and hydrogen peroxide scavenging assay were evaluated [9]. 
 
Statistical analysis
 
 
All the values were expressed as mean ±SEM. The data were statistically analyzed by one way ANOVA followed by Dunnett’s t-test. 
 
RESULTS   
Acute toxicity studies 
The test drugs S30 and S47 were showed safe upto a dose of 2000 mg/kg, bd.wt. with no signs of mortality, hence the dose of 
100 mg/kg and 200 mg/kg were considered for the study. 
 
Antimicrobial activity 
a. Antibacterial activity 
Minimum inhibitory concentration of S30 found to be Bacillus pumilus 50 µg/mL whereas remaining all strains minimum 
inhibitory concentration is 100 µg/mL. For S47 the minimum inhibitory concentration was found to be 500 µg/mL in all the strains. 
 
b. Antifungal activity 
Minimum inhibitory concentration of S30 in fungi is 100 µg/mL and S47 is 500 µg/mL. The standard drugs ciprofloxacin 
and fluconazole has shown MIC at concentration 10 µg/mL. 
 
Table: 1 Antibacterial activity and Antifungal of test drugs S30 and S47. 
 
Microorganisms S30 S47 Ciprofloxacin Fluconazole 
MIC Zone of  
(µg/ml) inhibition (mm) 
MIC Zone of (µg/ml) 
inhibition (mm)  
MIC Zone of (µg/ml) 
inhibition (mm)  
MIC Zone of (µg/ml) 
inhibition (mm)  
Bacillus subtilis 
Bacillus pumilis 
Escherichia coli 
Pseudomonas 
aureginosa 
Candida albicans 
Aspergillus 
fumigates       
100        14.0±0.57 
 50          11.3±0.33 
100        12.0±0.00 
100        12.6±0.66 
 
100        14.5±0.33 100        
16.5±0.50 
500     17.0±0.57 
500     16.3±0.33 
500     17.0±0.57 
500     17.6±0.88 
 
500     18.0±0.57 
500     20.3±0.33
 
10  22.3±0.54 
10  22.5±0.34 
10  22.6±1.20 
10  23.0±0.30 
         
          __                     
          __ 
                            __ 
                            __ 
                            __ 
                            __ 
10       23.0±0.66
 
10       24.0±0.33 
 
Anti-inflammatory activity 
a. Carrageenan induced paw edema models 
Percentage reduction in carrageenan induced paw edema of the test drug S30 at a dose of 100 mg/kg bd.wt and 200 mg/kg 
bd.wt were found to be 19.58% and 52.22% respectively. The percentage reduction in paw edema of the test drug S47 at a dose of 100 
mg/kg bd.wt and 200 mg/kg bd.wt were 10.80% and 44.22%. The standard drug indomethacin 10 mg/kg bd.wt has shown 65.27% 
reduction in paw edema. All the values were tabulated in table 2. The test drugs S30 and S47 have shown significant reduction in paw 
edema when compared to control and standard group. 
 
 
 
 
 
 
                                                   
www.iajpr.com 
P
ag
e8
4
0
7
 
Vol 7, Issue 04, 2017.                                                  Dr. M. Ganga Raju et al.                                                   ISSN NO: 2231-6876 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table: 2 Carrageenan induced anti-inflammatory activity of test drugs S30 and S47 in Sprague Dawley rats. 
 
 
  Change in paw edema  (mL)    
 
GROUPS 
              1h                     2h 3h 4 h % reduction in 
Paw edema at 3h 
  
 
Carrageenan control 
S30 (100 mg/kg) 
S30 (200 mg/kg) 
S47 (100 mg/kg)  
S47 (200 mg/kg) 
Indomethacin 
(10 mg/kg)                    
3.50±0.25 
3.33±0.05 
2.75±0.17 
3.33±0.05 
3.00±0.129 
2.41±0.20 
5.41±0.20 
4.83±0.21 
4.16±0.21 
4.41±0.20 
4.25±0.17 
3.41±0.20 
7.66±0.24 
6.91±0.20 
3.66±0.16 
6.83±0.21 
4.25±0.21 
4.33±0.16 
 
6.75±0.25 
6.33±0.16 
      --- 
19.58 %
a*
 
5.66±0.16 
6.88±0.08 
5.75±0.25 
3.58±0.20 
 52.22%
a* 
10.80%
a * 
44.22%
a* 
65.27%
a*
 
  
Values are expressed as mean±SEM, (n=6). All the groups were compared with control induced group and standard group. Significant 
values are expressed as control (a= p<0.01) standard (*=p<0.01) 
 
b. Formalin induced paw edema model 
The percentage reduction in formalin induced paw edema of the test drug S30 at a dose of 100 mg/kg bd.wt and 200 mg/kg 
bd.wt were found to be 19.00% and 38.08% respectively. The percentage reduction in paw edema of the test drug S47 at a dose of 100 
mg/kg bd.wt and 200 mg/kg bd.wt was 12.76% and 25.71%. The standard drug indomethacin 10 mg/kg has shown 64.28% reduction 
in paw edema. All the values were tabulated in table 3. The test drugs S30 and S47 have shown significant reduction in paw edema 
when compared to control and standard group. 
 
Table: 3 Formalin induced anti-inflammatory activity of test drugs S30 and S47 in Sprague Dawley rats. 
 
 
   Change in paw edema  (mL)   
 
GROUPS 
          
1h                     2h 
 
3h 
  
4 h 
% reduction in paw edema at  3h      
 
Formalin control 4.50±0.02 6.51±0.02 10.5±0.02 7.52±0.25       --- 
S30 (100 mg/kg) 5.52±0.02 7.13±0.04 8.51±0.02 7.00±0.08   19.00% 
a*
 
S30 (200mg/kg) 5.16±0.01 5.91±0.02 6.58±0.02 7.10±0.02   38.08%
 a* 
S47 (100mg/kg) 5.33±0.02 7.08±0.00 9.16 ±0.03 8.50 ±0.02       12.76%
a*
 
 S47 (200 mg/kg) 
Indomethacin 
(10 mg/kg) 
4.66±0.02 
2.04±0.00 
6.16±0.04 
3.52±0.02 
7.80±0.03 
 3.75±0.02 
7.61±0.04        25.71%
a*
 
3.32±1.20        64.28%
a*
 
 
Values are expressed as mean±SEM, (n=6). All the groups were compared with control induced group and standard group. Significant 
values are expressed as control (a= p<0.01) standard (*=p<0.01) 
 
Anti-Parkinson’s activity 
a. Reserpine induced Parkinson’s model 
The various parameters in reserpine induced Parkinson’s model like bradykinesia, ptosis, tremor, righting reflex muscular 
rigidity, catalepsy, locomotor behavior, actophotometer and swim test were measured. The values were reported in the Table 4 and 5. 
The reduction in symptoms of the test drug S30 and S47 at a dose of 100 mg/kg bd.wt, 200 mg/kg bd.wt was increased in dose 
dependent manner. The standard drug Bromocriptine has shown significant reduction in all the above parameters. All the results were 
tabulated in table 4 and 5.The test drugs S30 and S47 have shown significant reduction in all parameters when compared to control 
group, reserpine control and standard group. 
 
Table 4:  Reserpine induced Parkinson’s activity of test drugs S30 and S47 in Swiss albino mice 
 
GROUPS   Bradykinesia       Ptosis     Tremor  Righting reflex 
Control 39.5±1.50 --- --- --- 
Reserpine control 1.50±0.50
aA
 3.50±0.50
aA
 3.00±0.00
aA
 7.50±0.50
aA
 
S30 (100 mg/kg) 3.00±1.00
a*A
 2.50±0.50
a**B
 2.00±0.00
a*B
 1.50±0.50
a.**A
 
S30 (200 mg/kg) 9.50±0.50
a**A
 2.50±0.50
a**B
 1.5±0.00
a**B
 1.50±0.50
b**A
 
S47 (100 mg/kg) 3.50±0.51
a*B
 4.00±0.00
a*A
 3.00±0.0
a*A
 4.50±0.50
a**B
 
S47 (200 mg/kg) 6.50±0.50
a*A
 3.00±0.17
a**A
 2.00±0.00
a*A
 2.50±0.50
a*A
 
Bromocriptine 
(2.5 mg/kg) 
18.5±0.20
a**
 1.50±0.50
a**
 1.00±0.00
a**
 1.50±0.50
a**
 
Values are expressed as mean±SEM, (n=6). All the groups were compared with normal, reserpine induced group and standard group. 
Significant values are expressed as control (a= p<0.01) (b= p<0.05) reserpine control (**= p<0.01) (*= p<0.05)   standard (A=p<0.01) 
(B= p<0.05). 
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Table 5:  Reserpine induced Parkinson’s activity of test drugs S30 and S47 in Swiss albino mice. 
 
GROUPS Muscular rigidity Catalepsy   Actophotometer Righting reflex 
Control 89.0±1.0 2.00±0.0 230±10.0 260±1.00 
Reserpine control 6.00±0.5
aA
 165.0±5.00
aA
 8.00±1.00
aA
 15.0±5.00
aA
 
S30 (100 mg/kg) 37.5±2.5
a**B 
125±5.00
a**A 
11.5±0.50
a*A
 49.0±9.00
a*A
 
S30 (200 mg/kg) 56.5±0.1
a**B 
118±2.00
a**A 
15.5±0.50
a**A 
94.5±5.5
a**A
 
S47 (100 mg/kg) 22.5±7.5
a**B 
156±4.00
a*A
 12.0±1.0
b*A 
39.0±9.0
a**A 
S47 (200 mg/kg) 40.0±0.5
a**A
 116±1.50
a**A
 13.0±0.50
a*A
 69.0±1.0
a*B 
Bromocriptine (2.5 mg/kg) 58.5±3.5
a**
 65.0±5.0
a**
 26.0±1.00
a**
 125±5.0
b**
 
Values are expressed as mean±SEM, (n=6). All the groups were compared with normal, reserpine induced group and standard group. 
Significant values are expressed as control (a= p<0.01) (b= p<0.05)  reserpine control (**= p<0.01) (*= p<0.05)   standard 
(A=p<0.01) (B= p<0.05). 
 
b. Haloperidol induced Parkinson’s model 
The various parameters in haloperidol induced Parkinson’s model like bradykinesia, ptosis, tremor, righting reflex, muscular 
rigidity, catalepsy, actophotometer test were measured. The values were reported in the Table 6 and 7. The reduction in symptoms of 
the test drug S30 and S47 at a dose of 100 mg/kg bd.wt, 200 mg/kg bd.wt was increased in a dose dependant manner. The standard 
drug Bromocriptine has shown significant reduction in all the above parameters. All the results were tabulated in table 6 and 7. The 
two test drugs S30 and S47 have shown significant reduction in all parameters when compared to control group, haloperidol control 
and standard group. 
 
Table 6:  Haloperidol induced Parkinson’s activity of test drugs S30 and S47 in Sprague Dawley rats. 
 
GROUPS    Bradykinesia        Ptosis       Tremor  Righting reflex 
Control 50.5±1.50
 
--- --- --- 
Haloperidol control 12.0±0.50
bA
 3.50±0.50
aA
 3.00±0.00
aB
 7.00±0.50
aA
 
S30 (100 mg/kg) 3.50±0.50
a**B 
2.50±0.50
a*A 
2.00±0.00
a**A 
1.50±0.50
a**A 
S30 (200 mg/kg) 11.0±1.00
a**A
 2.00±0.50
a**B
 1.00±0.0
a**B
 1.50±0.50
a**A
 
S47 (100 mg/kg) 3.00±1.00
a*A
 3.00±0.00
a**A
 2.50±0.00
a*A
 4.50±0.50
a*A
 
S47 (200 mg/kg) 8.50±0.50
a**A 
3.00±0.00
b*A 
2.50±0.00
a**B
 4.00±0.00
a**A 
Bromocriptine (2.5 mg/kg) 16.50±1.50
a*
 1.50±0.50
a**
 1.00±0.00
a**
 2.00±0.00
b**
 
Values are expressed as mean±SEM, (n=6). All the groups were compared with normal, haloperidol induced group and standard 
group. Significant values are expressed as  control (a= p<0.01) (b= p<0.05)  haloperidol control (**= p<0.01) (*= p<0.05)   standard 
(A=p<0.01) (B= p<0.05). 
 
Table 7:  Haloperidol induced Parkinson’s activity of test drugs S30 and S47 in Sprague Dawley rats. 
 
GROUPS  Muscular rigidity       Catalepsy Actophotometer 
Control 
Haloperidol control 
60.0±0.0 
3.50±0.5
aA 
2.00±0.00 
165±5.00
bA
 
269±0.54 
25.0±5.00
aA
 
S30 (100 mg/kg) 12.5±2.05
a**A
 125±5.00
b**A
 33.0±1.00
a**B
 
S30 (200 mg/kg) 21.0±1.0
a**B
 118±2.00
a**B
 46.5±4.50
a**A
 
S47 (100 mg/kg) 19.0±1.00
a*A
 156±4.00
a*A
 29.6±0.50
a*A
 
S47 (200 mg/kg) 26.5±1.5
a**A
 116±1.50
a**A
 39.5±0.50
a**A
 
Bromocriptine (2.5 mg/kg) 31.0±0.50
a**
 65.0±5.00
a** 
57.5±0.20
a**
 
Values are expressed as mean±SEM, (n=6). All the groups were compared with normal, haloperidol induced group and standard 
group. Significant values are expressed as  control (a= p<0.01) (b= p<0.05)  haloperidol control (**= p<0.01) (*= p<0.05)   standard 
(A=p<0.01) (B= p<0.05). 
 
Histopathology 
In normal brain cerebral hemisphere appeared normal and meninges surrounding the brain appeared normal. In haloperidol 
control brain mild to moderate demyelination and necrosis noticed in the cerebral hemisphere of brain. In S30 treated brain mild foci 
of necrosis and inflammation noticed in the cerebral hemisphere. In S47 treated brain foci of hemorrhage or hematoma formation 
noticed in the cerebral hemisphere of brain. The standard bromocriptine treated brain. Cerebral hemisphere appeared normal-black and 
meninges surrounding the cerebral hemisphere appeared normal. 
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Normal                                     Haloperidol control                               S30 
 
 
 
S47                                   Bromocriptine 
 
Figure: 2 Histopathology of haloperidol induced parkinson’s model. 
 
Reducing power assay  
In vitro antioxidant activity was performed using reducing power assay. The IC50 concentrations of S30 and S47 are 42 
µg/mL and 49 µg/mL the standard ascorbic acid IC50 was found to be 31 µg/mL. From the results it is clear that the test drugs S30 and 
S47 showed significant antioxidant activity. 
 
H2O2 Scavenging assay 
In vitro antioxidant activity was performed using hydrogen peroxide scavenging assay. The IC50 concentrations of S30 and 
S47 are 16 µg/mL and 22 µg/mL the standard ascorbic acid IC50 was found to be 10 µg/mL. From the results it is clear that the test 
drugs S30 and S47 showed significant antioxidant activity. 
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DISCUSSION 
Acute toxicity studies of test drugs S30 and S47 at the dose of 2000 mg/kg showed no toxic symptoms or death in any of the 
animal’s upto one week and till the end of the study. Thus the drug was considered to be safe. 
In bacterial cells Hsp90 expressed as HtpG (High temperature protein G), a homologue of Hsp90. Under stress conditions, 
bacterial Hsp90 seems to be involved in supporting de novo protein folding [10]. As the test drugs (S30 and S47) are Hsp90 inhibitors, 
the antibacterial activity of these test drugs might be due to inhibition of high temperature protein G (HtpG). 
Fungi uses fungal Hsp90-calcineurin pathway in cell wall synthesis, ion homeostasis and other functions. Calcineurin function is 
governed by Hsp90 as it is one client protein of Hsp90. The antifungal activity of test drugs might be due to inhibition of fungal 
Hsp90 [11]. 
The two test drugs S30 and S47 100 mg/kg and 200 mg/kg showed (p<0.01) respectively. Histamine, vascular endothelial 
growth factor, acetyl  choline, oestrogen and fluid shear stress activates a mechanism in Hsp90. Hsp90 associates with endothelial 
nitric oxide synthase (eNOS) and is rapidly forms complex with eNOS  by agonist that stimulate the production of nitric oxide. So 
Hsp90 inhibitors impede the endothelial nitric oxide synthase that decreases the nitric oxide production [12]. Administration of two 
test drugs S30 and S47 to carrageenan induced rats and formalin induced rats have shown a dose dependent inhibition of the paw 
thickness and this might be due to blocking the eNOS through Hsp90 inhibition. 
The two test drug S30 and S47 100 mg/kg and 200 mg/kg showed (p<0.05) and (p<0.01) respectively. Hsp90 plays a role in 
maintaining the functional stability of neuronal proteins. Neurodegenerative disorders associated with protein aggregation, the 
rationale has been that inhibition of Hsp90 activates heat shock factor-1 (HSF-1) to induce production of Hsp70 and Hsp40, as well as 
of other chaperones, which in turn, promote disaggregation and protein degradation [13]. Administration of two test drugs S30 and 
S47 to reserpine induced and haloperidol induced Parkinson’s disease models have shown a dose dependent reduction in symptoms  
and this might be due to inhibition of Hsp90 which induces the Hsp70 and that leads to protein degradation. 
Additionally, histopathological examinations were also done to support the biochemical investigations. The histopathology 
studies of brain confirmed the anti-Parkinson’s activity of synthesized compounds S30 and S47. The brain of haloperidol treated 
group showed marked demyelination and necrosis in the cerebral hemisphere indicating the induction of Parkinson’s disease. The 
compounds treated groups showed significant variation from that of haloperidol induced group. The brain of S30 treated group 
showed mild foci of necrosis and inflammation without significant damage to meninges. The brain of S47 treated group showed 
hematoma formation in the cerebral hemisphere with considerable damage to meninges. The activity of S30 was found to be 
significant than S47 when compared to standard bromocriptine in which both cerebral hemisphere and meninges were normal.  
The two test compounds showed significant IC50 values in both models of antioxidant activity. The antioxidant activity might be due 
to presence of hydroxyl groups in the compounds. 
 
CONCLUSION 
It was concluded that the test drugs S30 and S47 possess antibacterial, antifungal, anti-inflammatory, anti-Parkinson’s and 
antioxidant activities. When the two test drug are compared to each other S30 has shown better anti-Parkinson’s, anti-inflammatory 
and antioxidant activities over S47. Further studies are required to elucidate the exact mechanism of action. 
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